About BIOAGE Labs Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://bioagelabs.com
Frequently Asked Questions
What is the 52-week range for BIOA?
The 52-week high is $25.955 and the 52-week low is $5.04.
What is the P/E ratio for BIOA?
The P/E ratio data is currently unavailable.
What is the dividend yield for BIOA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -28.99%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -912.25%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.74.
Analyst Recommendation Trends
Wall Street analyst consensus for BIOA over the last few months:
Latest BIOA News
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • ROTH Healthcare Opportunities Conference (New York, September 29, 2026): BJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, A
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioAge Labs, Inc. (BIOA) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 10:00 AM EDTCompany ParticipantsBJ Sullivan - Chief...
Roth Capital Reiterates Buy on Bioage Labs, Maintains $25 Price Target
Roth Capital analyst Adam Walsh reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $25 price target.
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity at week 12 Topline results expected in the second half of 2027 Beyond DME, results will inform development strategy in other NLRP3-driven retinal diseases, including geographic atrophy EMERYVILLE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge” or the “Company”),
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target
BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.
BioAge Labs Doses First Patient In Its Phsae 2 Study Of BGE-102 To Treat Diabetic Macular Edema
BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of
BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off
BioAge's diversified pipeline includes ophthalmology and apelin-APJ pathway programs, and partnerships with Novartis and Eli Lilly. See why BIOA stock is a buy.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-30 | Barton Shane | -7,861 | - | - |
| 2026-06-30 | Barton Shane | -4,065 | - | - |
| 2026-06-30 | Barton Shane | -4,000 | - | - |
| 2026-06-30 | Barton Shane | -4,290 | - | - |
| 2026-06-30 | Barton Shane | -20,216 | $25.1868 | $509,176 |
| 2026-06-30 | Barton Shane | +7,861 | $4.38 | $34,431 |
| 2026-06-30 | Barton Shane | +4,065 | $4.3 | $17,480 |
| 2026-06-30 | Barton Shane | +4,000 | $8.39 | $33,560 |
| 2026-06-30 | Barton Shane | +4,290 | $10.85 | $46,547 |
| 2026-06-29 | Barton Shane | -14,198 | - | - |
| 2026-06-29 | Barton Shane | -8,958 | - | - |
| 2026-06-29 | Barton Shane | -7,261 | - | - |
| 2026-06-29 | Barton Shane | -9,301 | - | - |
| 2026-06-29 | Barton Shane | -42,350 | $25.2084 | $1,067,576 |
| 2026-06-29 | Barton Shane | +14,198 | $4.38 | $62,187 |
| 2026-06-29 | Barton Shane | +8,958 | $4.3 | $38,519 |
| 2026-06-29 | Barton Shane | +7,261 | $8.39 | $60,920 |
| 2026-06-29 | Barton Shane | +9,301 | $10.85 | $100,916 |
| 2026-06-10 | Pande Vijay Satyanand | +22,000 | - | - |
| 2026-06-10 | Hemrajani Rekha | +22,000 | - | - |
| 2026-06-10 | Davidson Michael H. | +22,000 | - | - |
| 2026-06-10 | ENRIGHT PATRICK G | +22,000 | - | - |
| 2026-06-10 | HEALY JAMES | +22,000 | - | - |
| 2026-06-10 | GARNIER JEAN PIERRE | +22,000 | - | - |
| 2026-04-23 | GOLDSTEIN DOV A MD | -3,542 | - | - |
| 2026-04-23 | GOLDSTEIN DOV A MD | +3,542 | $4.38 | $15,514 |
| 2026-04-01 | RUBIN PAUL D | -3,383 | - | - |
| 2026-04-01 | RUBIN PAUL D | -5,437 | - | - |
| 2026-04-01 | RUBIN PAUL D | -8,820 | $17.81 | $157,084 |
| 2026-04-01 | RUBIN PAUL D | +3,383 | $6.57 | $22,226 |
| 2026-04-01 | RUBIN PAUL D | +5,437 | $4.11 | $22,346 |
| 2026-03-02 | RUBIN PAUL D | -2,000 | - | - |
| 2026-03-02 | RUBIN PAUL D | -5,433 | - | - |
| 2026-03-02 | RUBIN PAUL D | -7,433 | $20.3 | $150,890 |
| 2026-03-02 | RUBIN PAUL D | +2,000 | $6.57 | $13,140 |
| 2026-03-02 | RUBIN PAUL D | +5,433 | $4.11 | $22,330 |
| 2026-03-01 | GOLDSTEIN DOV A MD | -3,542 | - | - |
| 2026-03-01 | GOLDSTEIN DOV A MD | +3,542 | $4.38 | $15,514 |
| 2026-02-17 | Morgen Eric | +12,500 | - | - |
| 2026-02-17 | Morgen Eric | +110,000 | - | - |
| 2026-02-17 | Fortney Kristen | +330,000 | - | - |
| 2026-02-17 | Barton Shane | +45,000 | - | - |
| 2026-02-17 | RUBIN PAUL D | +110,000 | - | - |
| 2026-02-17 | GOLDSTEIN DOV A MD | +110,000 | - | - |
| 2026-02-02 | RUBIN PAUL D | -2,000 | - | - |
| 2026-02-02 | RUBIN PAUL D | -5,433 | - | - |
| 2026-02-02 | RUBIN PAUL D | -7,433 | $18.75 | $139,369 |
| 2026-02-02 | RUBIN PAUL D | +2,000 | $6.57 | $13,140 |
| 2026-02-02 | RUBIN PAUL D | +5,433 | $4.11 | $22,330 |
| 2026-02-01 | GOLDSTEIN DOV A MD | -3,541 | - | - |
| 2026-02-01 | GOLDSTEIN DOV A MD | +3,541 | $4.38 | $15,510 |
| 2026-01-16 | GOLDSTEIN DOV A MD | -3,542 | - | - |
| 2026-01-16 | GOLDSTEIN DOV A MD | +3,542 | $4.38 | $15,514 |
| 2026-01-13 | Fortney Kristen | -233,107 | $18.1163 | $4,223,036 |
| 2026-01-13 | GOLDSTEIN DOV A MD | -27,000 | - | - |
| 2026-01-13 | GOLDSTEIN DOV A MD | -1,923 | $21.0808 | $40,538 |
| 2026-01-13 | GOLDSTEIN DOV A MD | -11,663 | $20.5392 | $239,549 |
| 2026-01-13 | GOLDSTEIN DOV A MD | -4,440 | $19.4526 | $86,370 |
| 2026-01-13 | GOLDSTEIN DOV A MD | -8,974 | $18.4278 | $165,371 |
| 2026-01-13 | GOLDSTEIN DOV A MD | +27,000 | $8.39 | $226,530 |
| 2026-01-02 | RUBIN PAUL D | -2,000 | - | - |
| 2026-01-02 | RUBIN PAUL D | -5,433 | - | - |
| 2026-01-02 | RUBIN PAUL D | -7,433 | $12.8468 | $95,490 |
| 2026-01-02 | RUBIN PAUL D | +2,000 | $6.57 | $13,140 |
| 2026-01-02 | RUBIN PAUL D | +5,433 | $4.11 | $22,330 |
| 2025-12-09 | RUBIN PAUL D | -18,000 | - | - |
| 2025-12-09 | RUBIN PAUL D | -18,000 | $12 | $216,000 |
| 2025-12-09 | RUBIN PAUL D | +18,000 | $6.57 | $118,260 |
| 2025-12-04 | RUBIN PAUL D | -68,897 | - | - |
| 2025-12-04 | RUBIN PAUL D | -68,897 | $10.1878 | $701,909 |
| 2025-12-04 | RUBIN PAUL D | +68,897 | $4.11 | $283,167 |